Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study

Hepatology

Volumn 61, Issue 4, 2015, Pages 1145-1153

  Gragnani, Laura ^a,c   Fognani, Elisa ^a,c   Piluso, Alessia ^a,c   Boldrini, Barbara ^a   Urraro, Teresa ^a,c   Fabbrizzi, Alessio ^a,c   Stasi, Cristina ^a,c   Ranieri, Jessica ^a,c   Monti, Monica ^a,c   Arena, Umberto ^a,c   Iannacone, Claudio ^b   Laffi, Giacomo ^a,c   Zignego, Anna Linda ^a,c   Barbara, Boldrini ^c   Caini, Patrizio ^c   Villa, Giorgio La ^c   Moscarella, Stefania ^c   Romanelli, Roberto Giulio ^c   Guerra, Cristina Tosti ^c   Abbate, Rosanna ^c   Boddi, Maria ^c   Bosi, Alberto ^c   Rigacci, Luigi ^c   Pimpinelli, Nicola ^c   Moneglia, Martina ^c   Nacmias, Benedetta ^c   Pallanti, Stefano ^c   Sorbi, Sandro ^c   more..

^a UNIVERSITY OF FLORENCE   (Italy)

^b SPARC Consulting ^*  (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RITUXIMAB; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; CRYOGLOBULINEMIA; DEPRESSION; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PLASMAPHERESIS; PRIORITY JOURNAL; PRURITUS; PURPURA; SEX DIFFERENCE; SIDE EFFECT; SUSTAINED VIROLOGICAL RESPONSE; VIRAL CLEARANCE; WEAKNESS; WEIGHT REDUCTION; COHORT ANALYSIS; COMPLICATION; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; HEPACIVIRUS; MIDDLE AGED; PROSPECTIVE STUDY; TIME; VIROLOGY;

ANTIVIRAL AGENTS; COHORT STUDIES; CRYOGLOBULINEMIA; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TIME FACTORS;

EID: 84925354497     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27623     Document Type: Article

References (50)

1. Ferri C, La Civita L, Longombardo G, Zignego AL. Hepatitis C virus and mixed cryoglobulinaemia [letter; comment]. Br J Rheumatol 1994;33:301.
2. Zignego AL, Ferri C, Monti M, LaCivita L, Giannini C, Careccia G, et al. Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications. Clin Exp Rheumatol 1995;13:S33-S37.
3. Sansonno D, De Vita S, Iacobelli AR, Cornacchiulo V, Boiocchi M, Dammacco F. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998;160:3594-3601.
4. Zignego AL, Giannini C, Gragnani L. HCV and lymphoproliferation. Clin Dev Immunol 2012;2012:980942.
5. Zignego AL, Gragnani L, Giannini C, Laffi G. The hepatitis C virus infection as a systemic disease. Intern Emerg Med 2012;(7 Suppl. 3):S201-S208.
6. Craxi A, Laffi G, Zignego AL. Hepatitis C virus (HCV) infection: a systemic disease. Mol Aspects Med 2008;29:85-95.
7. Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E, et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clin Exp Rheumatol 1991;9:621-624.
8. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490-1495.
9. Casato M, Agnello V, Pucillo LP, Knight GB, Leoni M, Del Vecchio S, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997;90:3865-3873.
10. Frangeul L, Musset L, Cresta P, Cacoub P, Huraux JM, Lunel F. Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia. J Hepatol 1996;25:427-432.
11. Donada C, Crucitti A, Donadon V, Tommasi L, Zanette G, Crovatto M, et al. Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia. J Viral Hepat 1998;5:179-185.
12. Monti G, Pioltelli P, Saccardo F, Campanini M, Candela M, Cavallero G, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 2005;165:101-105.
13. Zignego AL, Craxi A. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis 2008;12:611-636, ix.
14. Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011;10:444-454.
15. Gragnani L, Fabbrizzi A, Triboli E, Urraro T, Boldrini B, Fognani E, et al. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study. Dig Liver Dis 2014;46:833-837.
16. Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000;27:2172-2178.
17. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006;54:3696-3706.
18. Sene D, Ghillani-Dalbin P, Thibault V, Guis L, Musset L, Duhaut P, et al. Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus. J Rheumatol 2004;31:2199-2206.
19. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
20. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
21. Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010;116:335-342.
22. Monti G, Saccardo F, Pioltelli P, Rinaldi G. The natural history of cryoglobulinemia: symptoms at onset and during follow-up. A report by the Italian Group for the Study of Cryoglobulinemias (GISC). Clin Exp Rheumatol 1995;(13 Suppl. 13):S129-S133.
23. De Vita S, Soldano F, Isola M, Monti G, Gabrielli A, Tzioufas A, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis 2011;70:1183-1190.
24. Zignego AL, Giannelli F, Marrocchi ME, Mazzocca A, Ferri C, Giannini C, et al. T(14;18) translocation in chronic hepatitis C virus infection. Hepatology 2000;31:474-479.
25. Zignego AL, Ferri C, Giannini C, Monti M, La Civita L, Careccia G, et al. Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med 1996;124:31-34.
26. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-1069.
27. Stasi C, Triboli E, Arena U, Urraro T, Petrarca A, Gragnani L, et al. Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. J Transl Med 2014;12:21.
28. Arena U, Vizzutti F, Abraldes JG, Corti G, Stasi C, Moscarella S, et al. Transient elastography (TE) is more effective for the identification of HCV patients with advanced (F3-F4) rather than significant (F2-F4) liver fibrosis. J Hepatol 2008;48:S284-S285.
29. Piluso A, Giannini C, Fognani E, Gragnani L, Caini P, Monti M, et al. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. J Viral Hepat 2013;20:e107-e114.
30. Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-3834.
31. Zignego AL, Ferri C, Giannelli F, Giannini C, Caini P, Monti M, et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002;137:571-580.
32. Ferri C, Marzo E, Longombardo G, Lombardini F, La Civita L, Vanacore R, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993;81:1132-1136.
33. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus [see comments]. N Engl J Med 1994;330:751-756.
34. Dammacco F, Sansonno D, Han JH, Shyamala V, Cornacchiulo V, Iacobelli AR, et al. Natural interferon-alpha versus its combination with 6-methyl- prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994;84:3336-3343.
35. Mazzaro C, Pozzato G, Moretti M, Crovatto M, Modolo ML, Mazzi G, et al. Long-term effects of alpha-interferon therapy for type II mixed cryoglobulinemia. Haematologica 1994;79:342-349. Erratum in Haematologica 1994;79:486.
36. Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005;52:911-915.
37. Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007;120:1034-1041.
38. Ferri C, Monti M, La Civita L, Longombardo G, Greco F, Pasero G, et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993;82:3701-3704.
39. Galli M, Zehender G, Monti G, Ballare M, Saccardo F, Piconi S, et al. Hepatitis C virus RNA in the bone marrow of patients with mixed cryoglobulinemia and in subjects with noncryoglobulinemic chronic hepatitis type C. J Infect Dis 1995;171:672-675.
40. Giannini C, Petrarca A, Monti M, Arena U, Caini P, Solazzo V, et al. Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. Blood 2008;111:2943-2945.
41. Laskus T, Radkowski M, Piasek A, Nowicki M, Horban A, Cianciara J, et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000;181:442-448.
42. Ducoulombier D, Roque-Afonso AM, Di Liberto G, Penin F, Kara R, Richard Y, et al. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 2004;39:817-825.
43. Abbate I, Lo Iacono O, Di Stefano R, Cappiello G, Girardi E, Longo R, et al. HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J Hepatol 2004;40:831-836.
44. Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 2002;99:3081-3086.
45. Antonelli A, Fallahi P, Ferrari SM, Corrado A, Sebastiani M, Giuggioli D, et al. Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. Clin Rheumatol 2013;32:1147-1154.
46. Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005;106:1175-1182.
47. Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clement S, et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011;33:1162-1172.
48. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 2014;13:272-280.
49. Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116:326-334.
50. Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, et al. Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 2014;73:831-837.